Cargando…
Human phase I metabolism of the novel synthetic cannabinoid 5F-CUMYL-PEGACLONE
PURPOSE: 5F-CUMYL-PEGACLONE is a recently emerged γ-carbolinone derived synthetic cannabinoid. The present study aimed to identify phase I metabolites to reliably prove consumption of the substance by urine analysis and to differentiate from the uptake of the non-fluorinated analog CUMYL-PEGACLONE....
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Japan
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315001/ https://www.ncbi.nlm.nih.gov/pubmed/30636984 http://dx.doi.org/10.1007/s11419-018-0447-4 |
_version_ | 1783384186677100544 |
---|---|
author | Mogler, Lukas Halter, Sebastian Wilde, Maurice Franz, Florian Auwärter, Volker |
author_facet | Mogler, Lukas Halter, Sebastian Wilde, Maurice Franz, Florian Auwärter, Volker |
author_sort | Mogler, Lukas |
collection | PubMed |
description | PURPOSE: 5F-CUMYL-PEGACLONE is a recently emerged γ-carbolinone derived synthetic cannabinoid. The present study aimed to identify phase I metabolites to reliably prove consumption of the substance by urine analysis and to differentiate from the uptake of the non-fluorinated analog CUMYL-PEGACLONE. METHODS: For metabolite characterization, phase I metabolites were analyzed by liquid chromatography–high resolution mass spectrometry after incubation with pooled human liver microsomes. Reliability of the biomarkers was evaluated by analysis of human urine samples (n = 20) by liquid chromatography–triple quadrupole tandem mass spectrometry. Sample preparation included β-glucuronidase treatment followed by liquid-liquid extraction. RESULTS: In total, 15 metabolites were detected in vivo and characterized. Metabolic reactions were primarily observed at the γ-carbolinone core and the 5-fluoropentyl chain, and included N-dealkylation, hydroxylation, hydrolytic defluorination, formation of a dihydrodiol, oxidation to the pentanoic acid metabolite and formation of the propionic acid metabolite. Six of these metabolites were identical with phase I metabolites of CUMYL-PEGACLONE, which must be considered for interpretation of analytical findings in urine samples. CONCLUSIONS: 5F-CUMYL-PEGACLONE was subject to extensive metabolism in humans. The propionic acid metabolite was the most abundant metabolite in all urine samples and should be targeted when maximum sensitivity is needed (e.g., drug abstinence control). However, this metabolite also occurs in the biotransformation of the non-fluorinated analog and is, therefore, not a compound-specific marker. For differentiation, a metabolite hydroxylated at the γ-carbolinone core showed to be the most reliable marker and should be used as an additional target analyte. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s11419-018-0447-4) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6315001 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer Japan |
record_format | MEDLINE/PubMed |
spelling | pubmed-63150012019-01-11 Human phase I metabolism of the novel synthetic cannabinoid 5F-CUMYL-PEGACLONE Mogler, Lukas Halter, Sebastian Wilde, Maurice Franz, Florian Auwärter, Volker Forensic Toxicol Original Article PURPOSE: 5F-CUMYL-PEGACLONE is a recently emerged γ-carbolinone derived synthetic cannabinoid. The present study aimed to identify phase I metabolites to reliably prove consumption of the substance by urine analysis and to differentiate from the uptake of the non-fluorinated analog CUMYL-PEGACLONE. METHODS: For metabolite characterization, phase I metabolites were analyzed by liquid chromatography–high resolution mass spectrometry after incubation with pooled human liver microsomes. Reliability of the biomarkers was evaluated by analysis of human urine samples (n = 20) by liquid chromatography–triple quadrupole tandem mass spectrometry. Sample preparation included β-glucuronidase treatment followed by liquid-liquid extraction. RESULTS: In total, 15 metabolites were detected in vivo and characterized. Metabolic reactions were primarily observed at the γ-carbolinone core and the 5-fluoropentyl chain, and included N-dealkylation, hydroxylation, hydrolytic defluorination, formation of a dihydrodiol, oxidation to the pentanoic acid metabolite and formation of the propionic acid metabolite. Six of these metabolites were identical with phase I metabolites of CUMYL-PEGACLONE, which must be considered for interpretation of analytical findings in urine samples. CONCLUSIONS: 5F-CUMYL-PEGACLONE was subject to extensive metabolism in humans. The propionic acid metabolite was the most abundant metabolite in all urine samples and should be targeted when maximum sensitivity is needed (e.g., drug abstinence control). However, this metabolite also occurs in the biotransformation of the non-fluorinated analog and is, therefore, not a compound-specific marker. For differentiation, a metabolite hydroxylated at the γ-carbolinone core showed to be the most reliable marker and should be used as an additional target analyte. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s11419-018-0447-4) contains supplementary material, which is available to authorized users. Springer Japan 2018-10-05 2019 /pmc/articles/PMC6315001/ /pubmed/30636984 http://dx.doi.org/10.1007/s11419-018-0447-4 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article Mogler, Lukas Halter, Sebastian Wilde, Maurice Franz, Florian Auwärter, Volker Human phase I metabolism of the novel synthetic cannabinoid 5F-CUMYL-PEGACLONE |
title | Human phase I metabolism of the novel synthetic cannabinoid 5F-CUMYL-PEGACLONE |
title_full | Human phase I metabolism of the novel synthetic cannabinoid 5F-CUMYL-PEGACLONE |
title_fullStr | Human phase I metabolism of the novel synthetic cannabinoid 5F-CUMYL-PEGACLONE |
title_full_unstemmed | Human phase I metabolism of the novel synthetic cannabinoid 5F-CUMYL-PEGACLONE |
title_short | Human phase I metabolism of the novel synthetic cannabinoid 5F-CUMYL-PEGACLONE |
title_sort | human phase i metabolism of the novel synthetic cannabinoid 5f-cumyl-pegaclone |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315001/ https://www.ncbi.nlm.nih.gov/pubmed/30636984 http://dx.doi.org/10.1007/s11419-018-0447-4 |
work_keys_str_mv | AT moglerlukas humanphaseimetabolismofthenovelsyntheticcannabinoid5fcumylpegaclone AT haltersebastian humanphaseimetabolismofthenovelsyntheticcannabinoid5fcumylpegaclone AT wildemaurice humanphaseimetabolismofthenovelsyntheticcannabinoid5fcumylpegaclone AT franzflorian humanphaseimetabolismofthenovelsyntheticcannabinoid5fcumylpegaclone AT auwartervolker humanphaseimetabolismofthenovelsyntheticcannabinoid5fcumylpegaclone |